Mosaic ImmunoEngineering Inc. financial data

Symbol
CPMV on OTC
Location
9114 Adams Ave., #202, Huntington Beach, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 19, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.54 % -0.65%
Debt-to-equity -101 % -0.01%
Return On Equity 9.53 % -43.8%
Return On Assets -763 % +44.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.24M shares
Common Stock, Shares, Outstanding 7.24M shares 0%
Entity Public Float 466K USD -43%
Common Stock, Value, Issued 72 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.24M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.24M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 64.1K USD -70.5%
General and Administrative Expense 554K USD -29.6%
Operating Income (Loss) -618K USD +38.5%
Nonoperating Income (Expense) -48.8K USD +17.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -667K USD +37.3%
Income Tax Expense (Benefit) 4.8K USD
Net Income (Loss) Attributable to Parent -672K USD +36.9%
Earnings Per Share, Basic 0 USD/shares +35.7%
Earnings Per Share, Diluted 0 USD/shares +35.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.8K USD +454%
Assets, Current 55.3K USD +38.4%
Assets 55.3K USD +38.4%
Accounts Payable, Current 134K USD -6.87%
Employee-related Liabilities, Current 4.14M USD +13.5%
Accrued Liabilities, Current 658K USD +0.66%
Liabilities, Current 5.91M USD +11.6%
Liabilities 7.36M USD +10.3%
Retained Earnings (Accumulated Deficit) -9.36M USD -7.73%
Stockholders' Equity Attributable to Parent -7.31M USD -10.1%
Liabilities and Equity 55.3K USD +38.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.1K USD +68.1%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 7.24M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.8K USD +454%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 3.5M USD +11.2%
Deferred Tax Assets, Operating Loss Carryforwards 686K USD +55.1%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 2.05M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%